Geopolitic / World
Track global geopolitics, strategic shifts, power competition and worldwide risk signals through structured summaries from curated sources.
US 18% Tariff Is Relief For India But Still Illegal Abhijit Das, Trade Specialist || The Gist
Summary
The United States has imposed 18% tariffs on Indian exports, while India may reduce its tariffs to zero, though the specifics remain unclear. President Trump claims India has agreed to significant purchases of US products and not to buy Russian oil, but these claims lack confirmation from India.
Conflicting perspectives exist regarding the US-India trade deal, particularly concerning the protection of Indian agricultural interests versus the opening of markets for US exports. The potential implementation of a tariff rate quota for certain US agricultural products raises concerns about market disruption and regulatory clarity on genetically modified crops.
The US is pursuing data exclusivity for pharmaceuticals for 5 to 10 years, which may hinder the entry of generics into the Indian market. There is uncertainty regarding the implications of a proposed $500 billion trade commitment from India to the US, particularly concerning market forces and compliance.
The details of the India-U.S. trade agreement remain unclear, particularly regarding the potential impact on India's agricultural standards. The assumption that India will comply with U.S. standards overlooks the potential for domestic resistance and legal challenges.
Perspectives
Analysis of the US-India trade deal and its implications.
Proponents of the Trade Deal
- Claim that the US has compelled countries to change their positions on tariffs
- Argue that the 18% tariff is a reduction from previous rates
- Highlight potential benefits of increased US agricultural exports to India
- Assert that the US seeks commitments from India on purchasing US products
Critics of the Trade Deal
- Warn that the 18% tariff remains illegal under WTO rules
- Question the validity of the trade deal without Indian confirmation
- Highlight concerns over the impact on Indian agricultural standards
- Doubt the feasibility of Indias compliance with the proposed $500 billion commitment
- Critique the lack of transparency in negotiations and potential market disruptions
Neutral / Shared
- Acknowledge that the fine print of the agreement is not yet available
- Note that negotiations have been ongoing since last February
- Recognize that the US has signaled a desire for non-discriminatory treatment in procurement
Metrics
trade_commitment
$500 billion USD
total size of India-US trade
This figure represents a significant target for bilateral trade growth.
$500 billion figure, you know, that Trump is doubting.
data_exclusivity_duration
5 to 10 years
duration for data exclusivity in pharmaceuticals
This could delay the entry of generics, impacting healthcare affordability.
US wants data exclusivity for anywhere between 5 to 10 years.
other
not yet available
details of the India-U.S. trade agreement
Lack of details complicates assessment of the agreement's implications.
the fine print of the agreement is not yet available
other
certain categories of agriculture products
potential conditions of the agreement
This could lead to significant changes in India's food safety laws.
for certain categories of agriculture products
other
plan B for imposing other sets of tariffs
U.S. strategy regarding tariffs
Indicates ongoing uncertainty in trade negotiations.
U.S. already had a plan B in place for imposing other sets of tariffs.
Key entities
Timeline highlights
00:00–05:00
The United States has imposed 18% tariffs on Indian exports, while India may reduce its tariffs to zero, though the specifics remain unclear. President Trump claims India has agreed to significant purchases of US products and not to buy Russian oil, but these claims lack confirmation from India.
- There is an understanding between the United States and India regarding tariffs, with the US imposing 18% tariffs on Indian exports while India may reduce its tariffs to zero. However, the specifics of which products this applies to remain unclear, leading to uncertainty about the deals framework
- President Trump has claimed that India has agreed not to purchase Russian oil and to commit to buying five hundred billion dollars worth of US energy and agricultural products. There is no confirmation from the Indian side regarding these claims, raising questions about the validity of the agreement
- The legality of the 18% tariffs under WTO rules is in question, as they are considered illegal. While there is a possibility to challenge these tariffs, the likelihood of India pursuing such a challenge is uncertain, especially given its past reluctance to confront US tariffs at the WTO
05:00–10:00
There are conflicting perspectives on the US-India trade deal, particularly regarding the protection of Indian agricultural interests versus the opening of markets for US exports. The potential implementation of a tariff rate quota for certain US agricultural products raises concerns about market disruption and regulatory clarity on genetically modified crops.
- There are conflicting perspectives regarding the US-India trade deal, particularly concerning the protection of Indian farmers, fishermen, and dairy interests versus the opening of Indian markets for US agricultural exports. This raises questions about how India will manage its tariff rates on various agricultural products, especially those of interest to the United States
- The possibility of implementing a tariff rate quota (TRQ) for certain US agricultural products is speculated, contingent on the quota size being a small share of Indian domestic consumption and the price of imported products being regulated. However, there are concerns that low prices due to US subsidies could disrupt the Indian market, highlighting the need for careful monitoring of these conditions
- There is uncertainty regarding the regulatory framework for genetically modified crops in India, as the US seeks more clarity on approval mechanisms. Additionally, the potential weakening of Indias intellectual property rights, particularly concerning Section 3D of the Indian Patents Act, raises doubts about commitments made by India and the implications for generic pharmaceuticals in the market
10:00–15:00
The US is pursuing data exclusivity for pharmaceuticals for 5 to 10 years, which may hinder the entry of generics into the Indian market. There is uncertainty regarding the implications of a proposed $500 billion trade commitment from India to the US, particularly concerning market forces and compliance.
- The US is seeking data exclusivity for pharmaceuticals for a period of 5 to 10 years, which could delay the entry of generics into the Indian market, raising concerns about affordable healthcare in India. There is uncertainty about how these issues will be resolved in the bilateral trade deal between India and the US
- President Trump has expressed doubt about a $500 billion figure related to India-US trade, which was previously agreed upon during Prime Minister Modis visit to the US. It is unclear whether Trumps reference to this figure pertains to a commitment by India to purchase US products, and if so, whether these purchases would be made irrespective of market forces
- There is speculation that India may have to concede ground on commitments related to customs duties and electronic transmissions, similar to what Indonesia experienced in its bilateral deal with the US. The speaker questions whether India can comply with any commitment to purchase $500 billion worth of goods from the US, suggesting that such a commitment would likely need to be spread over several years
15:00–20:00
The details of the India-U.S. trade agreement remain unclear, particularly regarding the potential impact on India's agricultural standards.
- The fine print of the India-U.S. deal is not yet available, leading to uncertainty about whether India will have to set aside its domestic agricultural standards in favor of U.S. standards. If the agreement mirrors what Malaysia accepted, there could be significant concerns regarding Indias food safety laws
20:00–25:00
The U.S. courts are currently reviewing the Trump-Racy Procult tariffs, with indications that the U.S.
- The U.S. courts are examining the Trump-Racy Procult tariffs, and even if they rule against them, there are reports that the U.S. has a plan B for imposing other tariffs. This raises doubts about the extent of relief that might be achieved if the tariffs are deemed illegal, suggesting that the situation may not lead to substantial changes
- The discussion raises questions about the effectiveness of individual countries taking on the U.S. in trade negotiations. It is speculated that if countries had united in their approach, the outcomes at the global level might have been different, indicating a missed opportunity for collective bargaining power
25:00–30:00
There is uncertainty regarding the platform for discussions, potentially influenced by China's presence. The timeline for early trade deal signings remains unclear, with skepticism about the usual legal scrutiny.
- There is uncertainty regarding the use of a specific platform for discussions, potentially influenced by the presence of China. The partnership between India, China, and Russia might have been a factor that could have encouraged Trump to adopt a more reasonable stance
- The timeline for any early signing of trade deals remains unclear, as these agreements are described as a separate species that do not adhere to traditional procedures. The speaker expresses doubt about whether the deals will undergo the usual legal scrutiny
- The conversation hints at the possibility of significant developments in trade negotiations, but there is skepticism about the nature of these developments. The speaker acknowledges the complexity of the situation and the need to wait for further clarity